Method for preparing rosuvastatin calcium intermediate
By using toluene/xylene mixed system, dynamic water removal and nitrogen protection in the rosuvastatin calcium intermediate synthesis process, the cyclic oxidation and amination sulfonation conditions are optimized, and the problems of by-product generation and low product purity in traditional processes are solved, and efficient and economical intermediate preparation is achieved.
Patent Information
- Application Number
- CN202510320062.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-03-18
- Publication Date
- 2025-06-27
AI Technical Summary
The traditional rosuvastatin calcium intermediate synthesis process has problems such as by-product generation, low product purity, high production cost and prolonged cycle.
The toluene/xylene mixed system is used as a solvent, combined with 3A molecular sieve dynamic water removal and nitrogen protection, and optimize the condensation reaction; the ethanol/acetic acid mixed solvent and DDQ batch temperature-controlled feed are used in the cyclic oxidation stage, and the amination sulfonation conditions are optimized and the DIBAL/NMO reduction oxidation system is used to reduce the generation of by-products and improve the purity of the product.
It significantly improves the balanced conversion rate of imine condensation, reduces by-product generation, improves product yield and purity, shortens production cycle, and reduces production difficulty and cost.
Smart Images

Figure CN120208881A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a method for preparing an intermediate of rosuvastatin calcium, belonging to the field of preparation of pharmaceutical intermediates. Background Art
[0002] As an efficient lipid-lowering drug, the synthesis process of the key intermediate of rosuvastatin calcium has always been a research focus in the field of medicinal chemistry. Traditional synthetic routes involve multiple steps of condensation, cyclization, and functional group modification reactions, and there are still many bottlenecks in actual industrial applications.
[0003] Taking a typical process as an example, benzene is often used as a solvent in the condensation reaction stage, and the condensation of 4-fluorobenzaldehyde and ethyl 4-methyl-3-oxopentanoate is carried out under the catalysis of piperidine / acetic acid. However, the high toxicity of benzene poses a serious threat to production safety, and the water generated during the reaction is difficult to effectively remove, resulting in the equilibrium conversion rate of imine condensation usually being lower than 80%. It is necessary to rely on column chromatography to purify the intermediate, significantly increasing the production cost. In the cyclization and oxidation stages, when directly using DDQ for oxidation in the prior art, it is easy to cause sulfur ether by-products and defluorination defects of aromatic rings due to local heat release, and the product purity is often lower than 90%. In addition, when m-chloroperbenzoic acid oxidizes thiopyrimidine to form a sulfonyl group, it is easy to cause the accumulation of sulfone sulfoxide by-products due to excessive oxidant, and it needs to be extracted and purified multiple times to meet the standards. In the subsequent amination and sulfonation reactions, the hydrolysis side reaction of methanesulfonyl chloride is difficult to inhibit, and the ester group reduction and oxidation steps often produce over-oxidized aldehyde products due to excessive reduction of DIBAL or insufficient oxidation selectivity of TPAP, ultimately leading to an extended batch production cycle and fluctuating yields.
[0004] In view of the above problems, there is an urgent need to construct an integrated process improvement plan: improving the condensation efficiency through green solvent substitution and dynamic water removal technology; developing a mixed solvent system and an accurate feeding strategy for oxidants to inhibit the generation of by-products; optimizing the amination and sulfonation conditions to achieve highly selective functional group conversion; and designing a direct utilization process of the intermediate without column chromatography, thereby comprehensively improving production economy and product quality. Summary of the Invention
[0005] The present invention aims at the above-mentioned defects existing in the prior art, provides a method for preparing an intermediate of rosuvastatin calcium, and solves the problems of reducing the generation of by-products, increasing the product yield, and reducing the production difficulty.
[0006] The object of the present invention is achieved through the following technical solutions. A method for preparing an intermediate of rosuvastatin calcium, the method comprising the following steps:
[0007] S1: Under nitrogen protection, react 4-fluorobenzaldehyde with ethyl 4-methyl-3-oxopentanoate in an organic solvent under reflux in the presence of piperidine acetate and a cocatalyst. Add 3A molecular sieve to remove the generated water in real time, and recover ethyl (2E)-2-[(4-fluorophenyl)methylideneamino]-4-methyl-3-oxopentanoate (Compound of Formula V) by vacuum distillation;
[0008] S2: In a mixed solvent, dropwise add 2-ethyl-2-isothiourea and the Compound of Formula VI to carry out a cyclization reaction under non-violent reflux conditions, and then add DDQ in batches for oxidation to obtain ethyl 4-(4-fluorophenyl)-6-isopropyl-2-methylthio-pyrimidine-5-carboxylate (Compound of Formula IV);
[0009] S3: Oxidize the Compound of Formula IV, monitor the progress of the oxidation reaction with potassium iodide test paper, immediately quench with saturated NaHCO3 after the reaction ends, and quickly extract to separate the unreacted oxidant to obtain ethyl 4-(4-fluorophenyl)-6-isopropyl-2-(methylsulfonyl)pyrimidine-5-carboxylate (Compound of Formula III);
[0010] S4: First treat the Compound of Formula III with methylamine, slowly dropwise add methanesulfonyl chloride under ice bath temperature control, mix at 0 °C and then gradually warm to room temperature for reaction for 12 h to capture HCl to obtain the Compound of Formula II;
[0011] S5: Reduce the ester group of the Compound of Formula II using DIBAL in anhydrous toluene to obtain an alcohol intermediate; then selectively oxidize, add 4A molecular sieve to adsorb moisture to obtain the final product ethyl 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonamido)-5-formyl-1-pyrimidine (Compound of Formula I).
[0012] Preferably, in step S1, the organic solvent is at least one of toluene and xylene, replacing the more toxic benzene solution in conventional production, with higher safety and a boiling point suitable for reflux.
[0013] Preferably, in step S1, the cocatalyst also includes at least one of p-toluenesulfonic acid and zinc chloride to accelerate the rate of the condensation reaction.
[0014] Furthermore, in step S1, add 3A molecular sieve to remove the generated water in real time to promote the forward movement of the imine condensation equilibrium.
[0015] Furthermore, in step S1, introduce nitrogen protection to avoid the oxidation of the sensitive raw materials containing fluorine aromatic rings.
[0016] Furthermore, in step S1, directly recover the solvent and unreacted raw materials by vacuum distillation to reduce the loss of column chromatography.
[0017] Preferably, in step S2, the mixed solvent in the cyclization stage is an ethanol / acetic acid mixed solvent, and the ratio of ethanol to acetic acid is 1:1. The ethanol / acetic acid mixed solvent is convenient for adjusting the polarity to promote cyclization.
[0018] Preferably, in step S2, the reaction temperature in the cyclization stage is maintained at 60 - 70 °C, and non-violent reflux reduces the thioether side reaction.
[0019] Preferably, in step S2, the feeding amount of DDQ is 1.1 - 1.2 eq. To avoid excessive oxidation resulting in defluorination of the aromatic ring, it is added in batches to control the reaction exotherm.
[0020] Preferably, in step S2, the mixed solvent in the oxidation stage is a dichloromethane / acetonitrile mixed solvent, and the ratio of dichloromethane to acetonitrile is 3:1. The dichloromethane / acetonitrile mixed solvent enhances the solubility of DDQ and improves the oxidation efficiency.
[0021] Furthermore, in step S2, 2-ethyl-2-isothiourea is added drop by drop to avoid poly-substitution side products caused by too high local concentration.
[0022] Preferably, in step S3, the oxidant is at least one of Oxone and m-CPBA, and Oxone is milder and has a lower cost.
[0023] Preferably, in step S3, the oxidation reaction temperature is controlled at 0 - 5 °C by an ice bath to prevent further oxidation of the sulfonyl group to sulfoximine.
[0024] Preferably, in step S3, the addition amount of the oxidant is 1.5 eq, and the reaction progress is monitored by potassium iodide test paper to avoid excess.
[0025] Preferably, in step S4, the addition amount of the methylamine ethanol solution is 2.5 eq to ensure complete nucleophilic substitution.
[0026] Furthermore, in step S4, the solvent is THF with moderate polarity to promote the contact between methylamine and the ester group.
[0027] Preferably, in step S4, the solvent for capturing HCl is at least one of triethylamine and DIPEA. Triethylamine (3 eq) or DIPEA is used to efficiently capture HCl to avoid hydrolysis of methanesulfonyl chloride.
[0028] Preferably, in step S4, the temperature gradient is to mix at 0 °C first and then gradually raise the temperature to room temperature for reaction for 12 hours to reduce the formation of by-products.
[0029] Preferably, in step S4, methanesulfonyl chloride needs to be added dropwise slowly, and the dropping time is more than 30 min, while controlling the temperature with an ice bath at 0 - 10 °C.
[0030] Preferably, in step S5, the addition amount of DIBAL is 1-1.2 eq. Excess is likely to cause over-reduction to hydrocarbons, and the end point is determined through a quenching experiment.
[0031] Preferably, in step S5, the reduction reaction is carried out at -78 °C, and then slowly warmed up to 0 °C and maintained for 2 hours.
[0032] Preferably, in step S5, the oxidant is at least one of NMO and TPAP, and N-methylmorpholine-N-oxide (NMO) is used to improve the oxidation efficiency.
[0033] Preferably, in step S5, the oxidation end point is quickly detected by an aldehyde group chromogenic reagent (2,4-dinitrophenylhydrazine).
[0034] In summary, compared with the prior art, the present invention has the following advantages:
[0035] 1. In the solution of the present invention, a toluene / xylene mixed system is used, which significantly reduces the poisoning risk while maintaining an appropriate boiling point. By introducing 3A molecular sieve for dynamic water removal and combining with nitrogen protection, the equilibrium conversion rate of the imine condensation reaction is greatly improved. Moreover, the process of directly recovering the solvent by vacuum distillation reduces raw material loss and avoids the high cost and low efficiency problems brought by traditional column chromatography. The synergistic effect of the cocatalyst greatly shortens the reaction time and effectively improves production economy;
[0036] 2. In the solution of the present invention, in the cyclization oxidation stage, the polarity is precisely regulated by an ethanol / acetic acid mixed solvent, and in combination with batchwise temperature-controlled feeding of DDQ, the content of sulfide by-products is successfully reduced, and at the same time, the generation of arene defluorination defects is avoided; Oxone is used for selective oxidation, and under ice bath conditions, it is monitored in real time by potassium iodide test paper, so that the conversion rate of the sulfonyl group reaches a relatively high level and the generation of sulfone sulfoxide by-products is reduced, significantly improving the product purity and reducing the risk of treatment with strong oxidants;
[0037] 3. In the solution of the present invention, in the amination sulfonation process, through a triethylamine / DIPEA scavenger system and gradient temperature control technology, the hydrolysis side reaction of methanesulfonyl chloride is inhibited within a small range, and at the same time, the efficient construction of the N-methylmethanesulfonamide group is ensured. The DIBAL / NMO reduction oxidation system is adopted, combined with low-temperature control and 4A molecular sieve dehydration, to improve the selectivity of ester group reduction, increase the aldehyde group generation rate in the oxidation stage and there is no over-oxidation product;
[0038] 4. In the solution of the present invention, the whole process adopts mild reaction conditions compatible with conventional equipment, avoiding equipment loss and safety risks brought by multiple high-temperature refluxes. The key intermediates (Formula III, Formula II) can be directly used for the next reaction without column chromatography purification, greatly shortening the batch production cycle and better meeting the requirements of continuous production. Brief Description of the Drawings
[0039] Figure 1 This is the synthetic route of the present invention. Detailed implementation manners
[0040] The technical solution of the present invention will be further specifically described below through specific embodiments, but the present invention is not limited to these embodiments.
[0041] Example 1
[0042] Under nitrogen protection, 4-fluorobenzaldehyde (24.8 g, 0.20 mol), ethyl 4-methyl-3-oxopentanoate (34.8 g, 0.22 mol), piperidine acetate (2.9 g, 20 mmol), p-toluenesulfonic acid (1.4 g, 8 mmol) and toluene (200 mL) were successively added to a 500 mL three-necked flask equipped with a mechanical stirrer, a thermometer and a water separator. 3A molecular sieve (20 g) was added, and the mixture was heated to 110 °C and refluxed for 6 h. The water generated was removed in real time through the 3A molecular sieve and the water separator. After the reaction was completed, toluene and unreacted raw materials were recovered by distillation under reduced pressure. The residue was filtered through a short silica gel column (eluent: petroleum ether / ethyl acetate = 10:1) to obtain a light yellow oily compound of formula V (45 g, yield 85%).
[0043] Example 2
[0044] Compound of formula V (42.26 g, 0.16 mol) was dissolved in a mixed solvent of ethanol / acetic acid (volume ratio 1:1, total 200 mL), and the temperature was raised to 65 °C. An ethanol solution (50 mL) of 2-ethyl-2-isothiourea (20.84 g, 0.20 mol) was added dropwise over 1 h. After holding the reaction for 3 h, the substrate was transferred to a mixed solvent of dichloromethane / acetonitrile (3:1, 300 mL) for dissolution, and DDQ (40.86 g, 0.18 mol) was added in three batches at intervals of 30 minutes, controlling the temperature ≤ 70 °C. After the reaction was completed, the solvent was removed by distillation under reduced pressure, and the insoluble matter was filtered off. The filtrate was concentrated and purified by column chromatography (eluent: dichloromethane / methanol = 50:1) to obtain a white solid compound of formula IV (43.1 g, yield 80.7%).
[0045] Example 3
[0046] Compound of formula IV (40.1 g, 0.12 mol) was dissolved in dichloromethane (300 mL), and the temperature was controlled at 0 - 5 °C in an ice bath. Oxone (27.4 g, 0.18 mol) was added in batches, and it was monitored with potassium iodide test paper until there was no blue color development, and the reaction was stirred for 2 h. The reaction solution was quenched with saturated NaHCO3 solution (200 mL). After liquid separation, the aqueous phase was extracted with dichloromethane (100 mL × 2). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain a light yellow solid compound of formula III (39.7 g, yield 90.3%).
[0047] Example 4
[0048] Dissolve the compound of formula III (36.61 g, 0.10 mol) in THF (200 mL), and cool it to 0 °C in an ice bath. Dropwise add the methylamine ethanol solution (40% w / w, 23.8 mL). After stirring for 30 minutes, slowly add methanesulfonyl chloride (17.18 mL, 0.15 mol), and control the dropping rate to keep the temperature ≤ 10 °C. After the addition is complete, remove the ice bath, and gradually warm up to room temperature and react for 12 h. Quench with triethylamine (38 mL, 0.30 mol), evaporate the solvent under reduced pressure, dissolve the residue in ethyl acetate (300 mL), and wash with water (100 mL × 2). After concentrating the organic phase, a white solid compound of formula II (35 g, yield 88.6%) is obtained.
[0049] Example 5
[0050] Dissolve the compound of formula II (31.6 g, 0.08 mol) in anhydrous toluene (300 mL), and cool it to -78 °C under nitrogen protection. Slowly add DIBAL-H (1.0 M toluene solution, 11 mL, 0.096 mol), keep the temperature for reaction for 1 h, then warm up to 0 °C and continue the reaction for 2 h. Quench with saturated sodium potassium tartrate solution, separate the layers, dry the organic phase with anhydrous magnesium sulfate, and concentrate to obtain an alcohol intermediate.
[0051] Dissolve the alcohol intermediate in acetonitrile (200 mL), add molecular sieve (20 g) and NMO (21.6 g, 0.16 mol), and stir at room temperature for 4 h. Detect with 2,4-dinitrophenylhydrazine test paper until there is no aldehyde group color development, filter off the molecular sieve, concentrate the filtrate, and obtain a white crystalline compound of formula I (23.26 g, yield 82.8%, purity 99.6%) by column chromatography (eluent: petroleum ether / ethyl acetate = 5:1).
[0052] The embodiments of the present invention are not limited to those described in the above examples. Without departing from the spirit and scope of the present invention, those of ordinary skill in the art can make various changes and improvements in form and detail, and all of these are considered to fall within the protection scope of the present invention.
Claims
1. A method for preparing a rosuvastatin calcium intermediate, characterized in that: The method comprises the following steps: S1: Under nitrogen protection, the raw material 4-fluorobenzaldehyde and 4-methyl-3-oxopentanoic acid ethyl ester are refluxed in an organic solvent under the catalysis of piperidine acetate and a co-catalyst, 3A molecular sieves are added to remove the generated water in real time, and (2E)-2-[(4-fluorophenyl)methylimino]-4-methyl-3-oxopentanoic acid ethyl ester (compound of formula V) is recovered by distillation under reduced pressure; S2: In a mixed solvent, 2-ethyl-2-isothiourea is added dropwise to the compound of formula VI for cyclization reaction under non-violent reflux conditions, and then DDQ is added in batches for oxidation to obtain 4-(4-fluorophenyl)-6-isopropyl-2-methylthiopyrimidine-5-carboxylic acid ethyl ester (compound of formula IV); S3: oxidizing the compound of formula IV, monitoring the progress of the oxidation reaction by potassium iodide test paper, quenching with saturated NaHCO3 immediately after the reaction is completed, and rapidly extracting to separate the unreacted oxidant to obtain ethyl 4-(4-fluorophenyl)-6-isopropyl-2-(methylsulfonyl)pyrimidine-5-carboxylate (compound of formula III); S4: first treat the compound of formula III with methylamine, slowly add methanesulfonyl chloride dropwise under ice bath temperature control, mix at 0°C, gradually heat to room temperature and react for 12h, capture HCl, and obtain the compound of formula II; S5: Using DIBAL to reduce the ester group of the compound of formula II in anhydrous toluene to obtain an alcohol intermediate; then selectively oxidize and add 4A molecular sieves to absorb moisture to obtain the final product 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonyl)-5-carboxylic acid ethyl ester-1-pyrimidine (compound of formula I).
2. A method for preparing a rosuvastatin calcium intermediate according to claim 1, characterized in that: In step S1, the organic solvent is at least one of toluene and xylene; and the co-catalyst further comprises at least one of p-toluenesulfonic acid and zinc chloride.
3. A method for preparing a rosuvastatin calcium intermediate according to claim 1, characterized in that: In step S2, the mixed solvent in the cyclization stage is an ethanol / acetic acid mixed solvent, and the ratio of ethanol to acetic acid is 1:1; the reaction temperature in the cyclization stage is maintained at 60-70°C.
4. A method for preparing a rosuvastatin calcium intermediate according to claim 1, characterized in that: In step S2, the feeding amount of DDQ is 1.1-1.2 eq; the mixed solvent in the oxidation stage is a dichloromethane / acetonitrile mixed solvent, and the ratio of dichloromethane to acetonitrile is 3:
1.
5. A method for preparing a rosuvastatin calcium intermediate according to claim 1, characterized in that: In step S3, the oxidant is at least one of Oxone and m-CPBA; in step S3, the oxidation reaction temperature is controlled at 0-5° C. by ice bath; and the amount of the oxidant added is 1.5 eq.
6. A method for preparing a rosuvastatin calcium intermediate according to claim 1, characterized in that: In step S4, the amount of methylamine ethanol solution added is 2.5 eq; the solvent for capturing HCl is at least one of triethylamine and DIPEA; methanesulfonyl chloride is added slowly, the addition time is greater than 30 min, and the temperature is controlled at 0-10° C. in an ice bath.
7. A method for preparing a rosuvastatin calcium intermediate according to claim 1, characterized in that: In step S5, the amount of DIBAL added is 1 to 1.2 eq; the reduction reaction is carried out at -78°C, then slowly heated to 0°C and maintained for 2 h.
8. A method for preparing a rosuvastatin calcium intermediate according to claim 1, characterized in that: In step S5, the oxidant is at least one of NMO and TPAP; in step S5, the oxidation endpoint is quickly detected by an aldehyde colorimetric reagent (2,4-dinitrophenylhydrazine).
Citation Information
Cited By
Synthesis method of rosuvastatin calcium parent nucleus
CN122213024A
